

**The FDA Office of Minority Health and Health Equity (OMHHE) &
UMD CERSI Virtual Public Workshop**

**Collaborating to Advance Health Equity for Diabetes
and Chronic Kidney Disease (CKD)**

Wednesday, February 10, 2021
10:00 am - 3:00 pm ET

OPENING SESSION: 10:00 – 10:15 a.m.

10:00-10:05 a.m.	Opening remarks	RADM Richardae Araojo, PharmD, MS	FDA Associate Commissioner for Minority Health
10:05-10:15 a.m.	Keynote Speaker	Lashawn McIver MD, MPH	Director of CMS Office of Minority Health

SESSION 1: 10:15 - 11:30 a.m.

**Using Patient Experience Data and Community/System Approach to Inform
Care, Drug Development and the Overall Research Agenda**

Purpose	Leverage patient experience data and community/system to inform care, drug development, and overall research agenda to improve patient outcomes and reduce health inequities for diverse communities with diabetes and chronic kidney disease (CKD).	
Moderator	Chanel F. Whittaker, PharmD, BCPS, CGP, FASCP	Associate Professor, University of Maryland School of Pharmacy
Panelists	Andrea Furia-Helms, MPH	Director, Office of Patient Affairs, FDA
	Richard Knight, MBA	President of the American Association of Kidney Patients (AAKP) Board of Directors
	Ann Bullock, MD	Director, Division of Diabetes Treatment and Prevention, Indian Health Service
	Rana Malek, MD	Clinical Associate Professor, University of Maryland School of Medicine
	Patrick Gee, PhD	Kidney Health Initiative (KHI) Patient Family Partnership Council (PFPC) Members

LUNCH BREAK: 11:30 – 12:30 p.m.

SESSION 2: 12:30-1:45 p.m.

Diversity in Clinical Trials in Diabetes and Chronic Kidney Disease (CKD)

Purpose	Explore barriers to diversity in clinical trials for CKD and diabetes and describe strategies to improve clinical trial diversity.	
Moderator	Christine Lee, PharmD, PhD	Strategic Research Engagement Lead, FDA OMHHE
Panelists	Milena Lolic, MD, MS	Lead Medical Officer, FDA
	Rekha Kambhampati, MD, MHS	Medical Officer, FDA
	Andreea Lungu, MD	Medical Officer, FDA
	Jovonni Spinner, DrPH, MPH, CHES	Senior Public Health Advisor, FDA
	Tesheia Harris, MBA, MHS	Deputy Director and Chief Operating Officer of YCCI and the Associate Director for Clinical Research for Yale School of Medicine

BREAK: 1:45-2:00 p.m.

SESSION 3: 2:00 - 3:00 p.m.

RWD Research in Diabetes and Chronic Kidney Disease (CKD)

Purpose	Utilization of real-world data to inform strategies and decision making on management of diabetes and CKD.	
Moderator	Charmaine Rochester - Eyeguokan, PharmD, CDCES (CDE), BCACP	Professor, University of Maryland School of Pharmacy
Panelists	Clydette Powell MD, MPH, FAAP	Designated Federal Officer, National Clinical Care Commission Medical Officer, Office of the Assistant Secretary for Health US Department of Health and Human Services
	Leonard Pogach, MD, MBA, FACP	National Program Director Diabetes and Endocrinology, Specialty Care Services, Veterans Health Administration
	Qi Liu, PhD, MStat, FCP	Senior Science Advisor Office of Clinical Pharmacology, Office of Translational Sciences Center for Drug Evaluation and Research, U.S. Food and Drug Administration
	Jenna Norton, PhD, MPH	Associate Director, Division of Kidney, Urologic, and Hematologic Diseases

3:00 - 3:05 p.m. - Closing remarks